Tower Research Capital LLC (Trc) Recursion Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,811 shares of RXRX stock, worth $30,886. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,811
Previous 34,063
85.88%
Holding current value
$30,886
Previous $255,000
87.84%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RXRX
# of Institutions
289Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$210 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$162 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$156 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$111 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$98.8 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.16B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...